Andere Sprachen Spyre Therapeutics, Inc.

Aktien

A3D4LY

US00773J2024

SYRE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
33,03 ^USD	-5,33 %		-3,56 %	+53,49 %

26.03.	SPYRE THERAPEUTICS, INC. : Stifel Nicolaus gibt eine Kauf-Bewertung ab	ZM
01.03.	SPYRE THERAPEUTICS, INC. : Von Wells Fargo Securities zum Kauf angehoben	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Steady Pre-Bell Friday	19.04.
Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	19.04.
Spyre Therapeutics Announces Grants of Inducement Awards	01.04.
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	18.03.
North American Morning Briefing : Powell Still in -2-	07.03.
Spyre Therapeutics Announces Grants of Inducement Awards	04.03.
North American Morning Briefing : Stock Futures -2-	04.03.
Spyre Therapeutics Announces Grants of Inducement Awards	01.03.
Spyre Therapeutics: Q4 Earnings Snapshot	29.02.
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29.02.
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	26.02.
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	09.02.
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	06.02.
Spyre Therapeutics, Inc. Announces Board Changes	05.02.
Spyre Therapeutics Announces Grants of Inducement Awards	02.02.
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	27.12.
Spyre Therapeutics Announces Grants of Inducement Awards	22.12.
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	08.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Spyre Therapeutics, Inc.

Aktien

A3D4LY

US00773J2024

SYRE

Andere Sprachen

Filter